Kilitch Drugs (India) Ltd. announced its unaudited financial results for the quarter ended December 31, 2025, during a board meeting held on February 11, 2026. For the quarter, the company reported a consolidated revenue of ₹53.81 Crores, reflecting a 10.00% increase from the previous quarter’s (QoQ) revenue of ₹48.92 Crores, but a 4.20% decrease compared to the corresponding quarter (YoY) of the previous year. The consolidated net profit for the quarter stood at ₹4.43 Crores, representing a sharp decline of 45.91% from the previous quarter’s profit of ₹8.19 Crores and a 25.67% decrease from the ₹5.96 Crores reported in the same quarter last year. Additionally, the board approved a bonus issue of 1 equity share for every 1 fully paid-up equity share held, subject to shareholder approval, and proposed increasing the authorized capital from ₹25 Crores to ₹40 Crores.

Kilitch Drugs (India) Ltd., established in 1978, is a global pharmaceutical manufacturer and marketer specializing in a diverse range of formulations, including ophthalmics, injectables, and oral solids. In 2025, the company made significant progress on its Greenfield Project in Pen, Maharashtra, a facility designed to meet international standards such as USFDA and EU GMP for manufacturing nutraceuticals and sterile products. During the year, the company successfully completed a rights issue of approximately ₹49.93 Crores to fund this expansion. Notable recent activity includes ace investor Mukul Agrawal acquiring a 1.3% stake in the company during the September 2025 quarter, valued at approximately ₹9 Crores. The company continues to strengthen its international presence, particularly in Africa, where it operates the largest Cephalosporin manufacturing plant in East Africa.